DNASE1 and inflammatory bowel disease: Although the exact mechanisms regarding the pathologic roles of NETs in IBD are not fully defined, DNase-I treatment in experimental settings has already shown promising outcomes against clinical manifestations of or disease associated with persistent NETs including SARS-CoV-2 and sepsis [17, 18].